← Eichor
Study identifier: NCT07732855 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Treatment of Ocular Surface Inflammations

Condition: Ocular Surface Allergy · Conjunctivitis, Allergic · Blepharoconjunctivitis  ·  Sponsor: Semmelweis University

PhaseN/A
Planned participants50
Who can joinAll sexes, 4 Years to 60 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn if topical Cyclosporine 1% works to treat severe allergic ocular surface inflammation in pediatric population. The study will evaluate the efficacy and safety of topical Cyclosporine 1%. The main questions it aims to answer are: Does topical Cyclosporine 1% lower the number of times participants need to use a rescue steroid? What medical problems do participants have when taking topical Cyclosporine 1%? Participants will: Take topical Cyclosporine 1% every day for months. Visit the clinic once every 2-6 weeks for checkups and tests. Keep a diary of their symptoms and the number of times they use a rescue medication. spelling errors/typos and update as appropriate.

This description comes directly from the study's public registry record.

Talk to the study team

Lim Lu Hyoun  ·  +3614591500  ·  luhyoun21c@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Semmelweis University Department of OphthalmologyBudapest, Pest County, HungaryRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07732855